Record #778134 - RWTH Publications

MICROB-PREDICT

MICROBiome-based biomarkers to PREDICT decompensation of liver cirrhosis and treatment response

Coordinator	ACADEMISCH ZIEKENHUIS LEIDEN ; EUROPEAN ASSOCIATION FOR THE STUDYOF THE LIVER ; EUROPEAN LIVER PATIENTS ASSOCIATION ; VAIOMER ; FUNDACIO INSTITUT CATALA DE NANOCIENCIA I NANOTECNOLOGIA ; Universitetet i Oslo ; University of London - University College London ; IT Consult ; EUROPEAN MOLECULAR BIOLOGY LABORATORY ; Biobyte Solutions (Germany) ; IT University of Copenhagen ; King's College London ; KU Leuven ; Atomic Energy and Alternative Energies Commission ; Autonomous University of Barcelona ; University of Debrecen ; Fundació Clínic per a la Recerca Biomèdica ; French National Institute for Agricultural Research ; ODENSE UNIVERSITETSHOSPITAL ; Max Planck Society ; European Foundation for the Study of Chronic Liver Failure ; Johann Wolfgang Goethe-Universtität Fachbereich Informatik und Mathematik Institut für Mathematik
Grant period	2019-01-01 - 2025-03-31
Funding body	European Union
Call number	H2020-SC1-2018-Single-Stage-RTD
Grant number	825694
Identifier	G:(EU-Grant)825694

Note: Decompensation of liver cirrhosis and progression towards acute-on-chronic liver failure (ACLF) causes 1.2 million deaths/year. Microbiome is causally involved in cirrhosis progression and is for drugs the first interaction point with the patients. Drugs can alter the microbiome leading to unwanted effects or even facilitating their effects, but the microbiome metabolizes the drugs, shapes their effects and possibly determines the host response to drugs. As each person carries an individual microbiome, insight in these processes should help stratify or even personalize patient health care and treatment. The aims of MICROB-PREDICT are 1) to better understand the role of microbiome and the gut-liver-axis interactome with respect to microbiome functionalities, 2) to identify and validate microbiome-based biomarkers and signatures for personalized prediction of decompensation and ACLF, and response to treatment, 3) to design three new tests as easy-to-use tools and point-of-care, smartphone-connected nanobiosensors, and 4) to validate them in a randomized controlled trial. MICROB-PREDICT will assemble existing data and samples from major microbiome initiatives in hepatology (12 international studies, >10,000 patients), and enrich them with holistic and in-depth analysis using cutting-edge multi-omics technologies of host and microbiome from different body sites in samples of >1,000 patients collected in a longitudinal manner with sequential visits and controlling for confounders. MICROB-PREDICT results will foster more accurate, personalized risk stratification and significant steps towards personalized treatment of decompensated cirrhosis and ACLF. World-leading microbiome specialists, technology leaders and clinical experts make this a programme of scientific excellence; patient organisations (ELPA) and the European Association for the study of the Liver (EASL) will channel our results into a powerful dissemination, communication and exploitation programme.